Dr Reddy's Laboratories Announced the First-to-Market Launch of Naloxone Hydrochloride Injection USP
News Desk, News Nation 360 : Dr Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr Reddy’s) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives, announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan® (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA). The Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) had U.S. sales of approximately $31 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health. Dr. Reddy’s Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) is available in 2 mL single-dose prefilled syringe. Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories said that they are pleased to bring their second product to market that has been designated as a Competitive Generic Therapy (CGT) by the USFDA with a CGT designation, they have 180-day CGT exclusivity to market this product.
Report : Anustup Kundu